Competitive electroporation formulation for cell therapy.

Competitive electroporation formulation for cell therapy.
复制标题

DOI:
10.1038/cgt.2011.27
复制
发表时间:
2011-08
影响因子:
6.4
通讯作者:
--
中科院分区:
医学3区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

通过核转染建立的细胞转染依赖于由于商业秘密而具有未知和专有组成的核转染缓冲液,抑制了使用这种原本有效的方法来开发细胞疗法的可能性。我们设计了一个三步法,用于发现任何细胞系的核转染的最佳制剂。这些步骤包括选择最佳核转染程序和已知的缓冲液类型,选择用于提高最佳缓冲液的转染效率的最佳聚合物,以及与来自已建立的商业供应商(Amaxa)的最佳缓冲液进行比较。使用该3步选择系统,发现了用于多种细胞系的竞争性核转染制剂,其在多种细胞和细胞系中的效率等于或超过Amaxa核转染剂溶液,包括原代脂肪干细胞、肌肉细胞、肿瘤细胞和免疫细胞。通过使用扫描电子显微镜,我们已经揭示了形态学的变化,这倾向于这些缓冲液的能力,以协助转移质粒DNA到核空间。我们的配方可以大大降低实验室电穿孔研究的成本,并提高了基于电穿孔的细胞疗法在临床试验中的应用潜力。
Established cell transfection via nucleofection relies on nucleofection buffers with unknown and proprietary makeup due to trade secrecy, inhibiting the possibility of using this otherwise effective method for developing cell therapy. We devised a three-step method for discovering an optimal formulation for the nucleofection of any cell-line. These steps include the selection of the best nucleofection program and known buffer type, selection of the best polymer for boosting the transfection efficiency of the best buffer, and the comparison with the optimal buffer from an established commercial vendor (Amaxa). Using this 3-step selection system, competitive nucleofection formulations were discovered for multiple cell lines, which are equal to or surpass the efficiency of the Amaxa nucleofector solution in a variety of cells and cell lines, including primary adipose stem cells, muscle cells, tumor cells, and immune cells. Through the use of scanning electron microscopy, we have revealed morphological changes, which predispose for the ability of these buffers to assist in transferring plasmid DNA into the nuclear space. Our formulation may greatly reduce the cost of electroporation study in laboratory and boosts the potential of application of electroporation-based cell therapies in clinical trials.
DOI: 10.1006/mthe.2001.0483
发表时间: 2001-11-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Hartikka, J;Sukhu, I;Sawdey, M
通讯作者: Sawdey, M
DOI: 10.1038/mt.2009.265
发表时间: 2010-02-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Josiah, Darnell T.;Zhu, Dongqin;Caldas, Hannah
通讯作者: Caldas, Hannah
DOI: 10.1016/j.bioelechem.2006.11.001
发表时间: 2007-05-01
影响因子: 5
作者:
Cukjati, David;Batiuskaite, Danute;Mir, Lluis M.
通讯作者: Mir, Lluis M.
DOI: 10.1155/jbb/2006/26060
发表时间: 2006
影响因子: --
作者:
Jacobsen F;Mertens-Rill J;Beller J;Hirsch T;Daigeler A;Langer S;Lehnhardt M;Steinau HU;Steinstraesser L
通讯作者: Steinstraesser L
DOI: 10.1016/j.jneumeth.2004.08.012
发表时间: 2005-03-15
影响因子: 3
作者:
Leclere, PG;Panjwani, A;Tonge, DA
通讯作者: Tonge, DA